Antifungal suscepitibility profile of Candida spp. oral isolates obtained from denture wearers

Brazilian Journal of Microbiology

Volumn 39, Issue 4, 2008, Pages 668-672

  Lyon, J P ^a,c   Moreira, L M ^a   Cardoso, M A G ^a   Saade, J ^a   Resende, M A ^b  

^a INSTITUTO DE PESQUISA E DESENVOLVIMENTO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c NONE   (Brazil)

Author keywords

Antifungal agents; Candida carriage; Denture wearers; Normal oral mucosa

Indexed keywords

CANDIDA;

EID: 59349103194     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822008000400013     Document Type: Article

References (28)

1. Barbeau, J.; Séguin, J.; Goulet, J.P; Koninck, L.; Avon, S.L.; Lalonde, B.; Rompré, P.; Deslauriers, N. (2003). Reassessing the presence of Candida albicans in denture related stomatitis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont., 95, 51-59.
2. Belazi, M.; Velegraki, A.; Koussidou-Eremondi, T.; Andreadis, D.; Hini, S.; Arsenis, G.; Eliopoulou, C.; Destouni, E.; Antoniades, D. (2004). Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol. Immunol., 19, 347-351.
3. Burn, K.A.; Fothergill, A.W.; Kirkpatrick, W.R.; Coco, B.J.; Patterson, T.F.; McCarthy, D.I.; Rinaldi, M.G.; Redding, S.W. (2004). Comparison of Antifungal Susceptibilities to Fluconazole and Voriconazole of Oral Candida glabrata Isolates from Head and Neck Radiation Patients. J. Clin. Microbiol., 42, 5846-5848.
4. Costa, C.R.; de Lemos, J.A.; Passos, X.S.; de Araújo, C.R.; Cohen, A.J.; Souza, L.K.; Silva, M.R.R. (2006). Species distribution and antifungal susceptibility profile of oral Candida isolates from HIV-infected patients in the antiretroviral therapy era. Mycopathologia. 162, 45-50.
5. Cross, L.J.; Bagg, J.; Wray, D.; Aitchison, T. (1998). A comparison of fluconazole and itraconazole in the management of denture stomatitis: A pilot study. J. Dentist., 26, 657-664.
6. Cross, L.J.; Willians, D.W.; Sweeney, C.P.; Jackson, M.S.; Lewis, M.A.O.; Bagg, J. (2004). Evaluation of the recurrence of denture stomatitis and Candida colonization in a small group of patients who received itraconazole. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont., 97, 351-358.
7. Ghannoum, M.A.; Rice, L.B. (1999). Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Micobiol. Rev., 12, 501-17.
8. Haberland-Carrodeguas, C.; Allen, C.M.; Beck, F.M.; Bueschiling, W.J.; Koletar, S.L.; Sundstron, P. (2002). Prevalence of fluconazole-resistant strains of Candida albicans in otherwise healthy outpatients. J.Oral Pathol. Med., 31, 99-105.
9. Jessup, C.J.; Ryder, N.S.; Ghannoum, M.A. (2000). An evaluation of the in vitro activity of Terbinafine. Med. Mycol., 38, 155-159.
10. Kuriyama, T.; Williams, D.W.; Bagg. J.; Coulter, W.A.; Ready, D.; Lewis, M.A.O. (2005). In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol. Immunol., 20, 349-353.
11. Kurtzman, P.C.; Fell, J.W. (1998). The yeasts: a taxonomic study. Amsterdam: Elsevier.
12. Lanfon, H.; Al-Karaawi, Z.; Mc Collough, M.; Porter, S.R.; Pratten, J. (2005). Composition of in vitro denture plaques biofilms and susceptibility to antifungal. FEMS Microbiol. Lett., 242, 345-341.
13. Lyon, J.P.; Costa, S.C.; Totti, V.M.G.; Munhoz, M.F.; Resende, M.A. (2006). Predisposing conditions for Candida spp. carriage in the oral cavity of denture wearers and individuals with natural teeth. Canadian J. Microbiol., 52, 462-467.
14. Manfredi, M.; McCullough, M.J.; Polonelli, L.; Conti, S.; Al-Karaawi, Z.M.; Vescovi, P.; Porter, S.R. (2006). In vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitus. Oral Microbiol Immunol., 21, 177-82.
15. National Commitee for Clinical Laboratory Standards (2002). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard (NCCLS document M27-A2) Villanova, PA: National Committee for Clinical Laboratory Standards.
16. Perea S, Gonzalez G, Fothergill, AW, Sutton, DA, Rinaldi, MG (2002). In vitro activities of terbinafine in combination with fluconazole, voriconazole and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J. Clin. Microbiol., 40: 1831-1833.
17. Petranyi, G.; Meingassner, J.G.; Mieth, H. (1987). Antifungal activity of the allylamine derivative Terbinafine in vitro. Antimicrob. Agents Chemother., 31, 1365-1368.
18. Pfaller, M.A.; Diekema, D.J.; Messer, S.A.; Boyken, S.; Hollis, R.J.; Jones, R.N. (2003). In vitro activities of Voriconazole, Posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J.Clin. Microbiol., 41, 78-83, 2003.
19. Ramage, G.; Tomsett, K.; Wichers, B.L.; Lopez-Ribot, J.L.; Redding, S.W. (2004). Denture stomatitis: A role for Candida biofilms. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont., 98, 53-59.
20. Rautemaa, R.; Richardson, M.; Pfaller, M.; Koukila- Kähkölä, P.; Perheentupa, J.; Saxén, H. (2007). Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. J. Antimicrob Chemother., 60, 889-892.
21. Resende, M.A.; Souza, L.V.N.F.; Oliveira, R.C.B.W.; Koga-Ito, C.Y.; Lyon, J.P. (2006). Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals. Mycopathologia, 162, 39-44.
22. Rex, J.H.; Pfaller, M.A.; Walsh, T.J.; Chaturvedi, V.; Espinel-Ingroff, A.; Ghannoum, M,A,; Gosey, L.L.; Odds, F,C.; Rinaldi, M.G.; Sheehan, D.J.; Warnock, D.W. (2001). Antifungal susceptibility testing: Pratical aspects and current challenges. Clin. Microbiol. Rev., 14, 643-658.
23. Rubio Calvo, M.C.; Gil, J.; De Ocaris, I.R.; Benito, R.; Rezusta, A. (2003). In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp. Rev. Espanol. Quimioter, 16, 227-232.
24. Ryder, N.S. (1999) Activity of terbinafine against serious fungal pathogens. Mycoses, 42, 115-119.
25. Ryder, N.S.; Favre, B. (1997). Antifungal activity and mechanism of action of Terbinafine. Pharmacotherapy, 8, 275-287.
26. Ryder, N.S.; Wagner, S.; Leitner, I. (1998). In Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts. Antimicrob. Agent. Chemother., 42, 1057-1061.
27. Swoboda-Kopec, E.; Wroblewska, M.; Rokosz, A.; Krawezyk, E.; Luczac, M. (2003). Susceptibility of clinical isolates of Candida glabrata to new triazoles. Int. J. Antimicrob. Agents, 21, 360-361.
28. Winterger, M.A.; Guilhermetti, E.; Shinobu, C.S.; Takaki, I.; Svidzinski, I.E. (2007). Microbiological identification and in vitro sensitivity of Candida. Rev. Soc. Bras. Med. Trop., 40, 272-276.